Trial Profile
Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms RTOG
- 29 Apr 2014 Added a group (non-adjuvant) to the treatment table and modified the existing groups as reported by ClinicalTrials.gov.
- 29 Apr 2014 According to ClinicalTrials.gov record, status changed from completed to active, no longer recruiting.
- 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.